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Abstract About 15–20% of human cancers worldwide have
viral etiology. Emerging data clearly indicate that several human
DNA and RNA viruses, such as human papillomavirus,
Epstein–Barr virus, Kaposi’s sarcoma-associated herpesvirus,
hepatitis B virus, hepatitis C virus, and human T-cell lympho-
tropic virus, contribute to cancer development. Human tumor-
associatedviruseshaveevolvedmultiplemolecular mechanisms
to disrupt specific cellular pathways to facilitate aberrant
replication. Although oncogenic viruses belong to different
families, their strategies in human cancer development show
many similarities and involve viral-encoded oncoproteins
targeting the key cellular proteins that regulate cell growth.
Recentstudies showthatvirusandhostinteractionsalsooccurat
the epigenetic level. In this review, we summarize the published
information related to the interactions between viral proteins and
epigenetic machinery which lead to alterations in the epigenetic
landscape of the cell contributing to carcinogenesis.
Keywords Epigenetics.DNA methylation.Histone
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Viruses and cancer
Cancer research over the past five decades has revealed
important role of viral infections in human cancer. Viral etiology
of human neoplasms was first discovered at the turn of the
nineteenth century, when Ciuffo and co-workers demonstrated
that human warts can be transmitted by cell-free filtrates derived
fromlesions(Ciuffo1907). Several years later, in 1911, P. Rous
identified the first animal tumorigenic virus (Rous sarcoma
virus) that induces development of spindle cell sarcoma in
birds. The first human tumor-associated virus was discovered
more recently, in 1964, by Michael Anthony Epstein and
Yvonne Barr and was named Epstein–Barr virus (EBV).
Recent studies have shown the infectious etiology of
several cancers. It has been estimated that 15–20% of all
human cancers worldwide are caused by oncogenic viruses
(Butel 2000). Viruses associated with cancer belong to
different phylogenetic groups. They include both DNA
viruses, e.g., human papillomaviruses (HPV), hepatitis B
virus (HBV), the herpesviruses such as EBV and Kaposi’s
sarcoma-associated herpesvirus (KSHV), and RNA viruses
such as retroviruses, e.g., human T-cell lymphotropic virus
1 (HTLV-1), and the RNA flavivirus, hepatitis C virus
(HCV). The causal contribution of the above-mentioned
viruses to the development of human neoplasms is now
well documented. Besides these, there are other viruses
with a potential influence on human carcinogenesis.
Recently, an integrated form of a new polyomavirus,
MCPyV, has been detected in patients with the Merkel cell
carcinoma (zur Hausen 2008; Feng et al. 2008). Other
polyomaviruses, such as SV40, JCV, and BKV, and
adenoviruses may play possible role in human carcinogen-
esis as well. Polyomaviruses are tumorigenic under exper-
imental conditions, and their genomic sequences were
detected in samples derived from several human cancers,
e.g., human osteosarcoma, mesotelioma, brain tumors,
prostate cancer, and NHL; however, no definite proof exists
that these viruses directly contribute to human cancer
(McCabe et al. 2006; Goel et al. 2006; Feng et al. 2008;
Jiang et al. 2009). Certain serotypes of adenoviruses are
also highly transforming in cell culture and in animal
models but adenovirus DNA was generally not detected in
human tumor cells. However, one study reported detection
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2007), therefore the possible contribution of adenoviruses
to human oncogenesis should be considered.
Some viruses, e.g., HBV, HCV, HTLV-1, are linked to a
single cancer type whereas some viruses, such as HPV,
EBV, and KSHV, contribute to multiple cancer types.
Prevalence of several viruses is particularly high in certain
cancer types. For example, HPV is associated with 95% of
cervical cancers, human HBV and human HCV are
associated with 80% of hepatocellular carcinomas (HCCs),
and EBV is positive in 30% of Hodgkin’s lymphomas (zur
Hausen 2006). A summary of the human viruses associated
with cancer development is listed in Table 1.
Unlike acute-transforming animal retroviruses, human
oncoviruses lead to cancer development with prolonged
persistent infections. Additional factors such as environ-
mental carcinogens, host cell mutations, and immune
response also take part in viral-associated carcinogenesis.
Viral strategies in human cancer development are diverse,
depending on virus species and cell type they affect.
Despite this, they share many common features. All human
tumor-associated viruses encode oncoproteins essential for
viral replication that disrupt cellular processes, such as
apoptosis and cell-cycle checkpoint control (Butel 2000;
McLaughlin-Drubin and Munger 2008). The main cellular
targets of viral oncoproteins are p53 and RB, although
recent studies also report other targets like nuclear factor
κB (NFκB), hTERT, and TRAFs (Oliveira 2007;O ’Shea
2005). The oncoproteins play very important role in viral
life cycle. Because DNA oncoviruses rely on the cellular
DNA replication machinery for propagation and most of
them infect quiescent cells, which are not optimal for viral
DNA replication, they evolved oncoproteins targeting the
central cellular hubs regulating cell growth. This mecha-
nism enables oncoviruses to force quiescent cells into
unscheduled S-phase entry thus leading to concomitant
DNA viral genome replication with host DNA. Deregulation
of apoptosis and cell-cycle checkpoint control induced by
tumorigenic viruses subsequently leads to an increase in
cellular DNA mutations and genome instability (Butel 2000;
Oliveira 2007;O ’Shea 2005).
Recent cancer research provides the emerging informa-
tion on the molecular events underlying the tumorigenic
potential of human oncoviruses. During last two decades,
significant progress has been made towards understanding
the viral oncogenetic mechanisms. It has been demonstrated
that the virus/host interactions that contribute to cancer
development also occur at the epigenetic level.
The epigenetic state of cancer cell differs significantly
from that of the normal cell. Cancer cells are characterized
by multiple epigenetic alterations including DNA methyl-
ation and histone modification. Compared to the normal
cells, cancer cells contain hypermethylated CpG islands in
promoters of specific sets of genes and genome-wide
hypomethylated DNA mainly in the body of genes and
intergenic regions (Suzuki and Bird 2008; Esteller 2007;
Kulis and Esteller 2010). The analysis of cancer cells
epigenomes also revealed numerous aberrations in histone
modifications including histone acetylation and methyla-
tion. These epigenetic aberrations lead to inappropriate
gene expression that contributes to cancer development
(Esteller 2007; Chi et al. 2010; Biancotto et al. 2010).
Increasing evidence reveals that oncogenic viruses also
contribute to the epigenetic changes that are characteristic
Virus Taxonomy Genome Human cancer
HPV Papillomaviridae dsDNA Cervical cancer, Anal cancer, Penis
cancer, Head and neck carcinoma
EBV Herpesviridae dsDNA Burkitt’s lymphoma, Hodgkin’s
lymphoma, Posttransplantation
lymphoma, Nasopharyngeal carcinoma
KSHV (HHV-8) Herpesviridae dsDNA Kaposi’s sarcoma, Pleural effusion
lymphoma, Multicentric Castleman’s
disease
HBV Hepadnaviridae dsDNA Hepatocellular carcinoma
HCV Flaviviridae ssRNA Hepatocellular carcinoma
HTLV-1 Retroviridae ssRNA-dsDNA Adult T-cell leukemia
MCV Polyomaviridae dsDNA Merkel cell carcinoma
SV40 Polyomaviridae dsDNA Mesothelioma and colon tumors
JCV Polyomaviridae dsDNA Brain and colon tumors
BKV Polyomaviridae dsDNA Prostate and brain tumors
Adenovirus Adenoviridae dsDNA Several serotypes can transform human and
rodent cells and cause malignant tumors
upon injection into rodents
Table 1 Viruses associated with
human cancer development
HHV-8 human herpesvirus 8
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host epigenetic machinery and cause aberrations of DNA
methylation as well as changes in histone modifications.
Many studies have shown that viral oncoproteins induce
expression and interact with cellular DNA methyltransferases
(DNMTs) as wellas histone-modifying enzymes,e.g., histone
deacetylases (HDACs), histone acetyltransferases (HATs),
histone methyltransferases, and demethylases changing their
activity(Burgersetal. 2007; Ferrari et al. 2009; McLaughlin-
Drubin et al. 2011). Viral proteins are also able to alter the
activity of proteins associated with the chromatin-remodeling
complexes and miRNA processing (Flanagan 2007;J a v i e r
and Butel 2008;W h i t b y2009).
Viruses that are able to integrate their genomes into host
DNA often activate host defense mechanism that is
responsible for the inactivation of integrated foreign genetic
material by DNA methylation (Doerfler 1991a; 1996;
2009). Moreover, viral DNA methylation can be a masking
mechanism that helps to avoid viral proteins recognition by
the immune system during latent infections (Fernandez et
al. 2009).
This review summarizes the information available about
the epigenetic mechanisms used by human oncogenic
viruses in human tumorigenesis. We describe the interac-
tions between viral proteins and host epigenetic machinery
and their consequences for the host cell epigenome and the
viral life cycle.
Human papillomaviruses
HPV are small non-enveloped DNA viruses which infect
epithelial cells and their life cycle depends on epithelial
differentiation and viral–host protein interaction (Doorbar
2005, 2006). More than 100 different types of HPV have
been identified and classified into low- or high-risk groups
depending on their likelihood of inducing cervical cancer
(zur Hausen 2009). Cervical cancer is one of the most
common cancer among women worldwide and is strongly
linked to infection by high-risk human papillomaviruses,
mainly HPV16 and HPV18 types (de Villiers et al. 2004;
zur Hausen 2009).
HPV E6 and E7 early proteins are the major HPV
oncogenic proteins, which induce proliferation, immortali-
zation, and malignant transformation of the infected cells.
The key event in cervical carcinogenesis is integration of
HPV genome into the host cell chromosome. In this case,
virus is not able to complete its productive life cycle, and
viruses are not released from infected cells, but can persist
in the host cells and initiate oncogenesis. The integration
frequently disrupts the E1-E2 genome region, resulting in a
loss of E2 viral gene expression. E2 protein is a
transcriptional repressor of E6 and E7 gene expression.
T h e r e f o r e ,d e r e g u l a t i o no fE 2e x p r e s s i o nl e a d st oa n
increase in expression of both E6 and E7 oncoproteins.
Interactions between high-risk HPV16 E6 and E7 proteins
and human tumor suppressor gene products p53 and
retinoblastoma (RB), respectively, lead to functional inac-
tivation of these critical cell regulatory proteins and thus
contribute to tumorigenesis process.
Epigenetic alterations such as changes in DNA methyl-
ation pattern of viral and host genome as well as histone
modification are very often associated with HPV infection
and cervical carcinogenesis. Methylation of HPV DNA
takes place regularly in vivo in cervical cells, clinical
samples as well as in cell cultures. (Badal et al. 2003, 2004;
Kim et al. 2003; van Tine et al. 2004; Kalantari et al. 2004;
Wiley et al. 2005; Turan et al. 2006; Bhattacharjee and
Sengupta 2006). It has been suggested that de novo
methylation of HPV DNA might be a host defense
mechanism for silencing viral replication and transcription
or strategy that virus uses to maintain a long-term infection
(Remus et al. 1999; Badal et al. 2003). HPV genome does
not encode any known protein involved in DNA methyl-
ation machinery, therefore it is believed that the viral
genome as well as the host genome is methylated by human
host cell DNMT (Fernandez and Esteller 2010). The pattern
of HPV genome methylation changes and depends on the
stage of viral life cycle, and the presence of disease and
probably the viral type (Woodman et al. 2007). Viral DNA
hypermethylation is more closely associated with carcino-
mas than with asymptomatic infections or dysplasia
(Fernandez et al. 2009). DNA hypermethylation has been
observed in long control region (LCR) and L1 region of
HPV genome (Badal et al. 2003, 2004; Kim et al. 2003;
Kalantari et al. 2004; Bhattacharjee and Sengupta 2006;
Turan et al. 2007; Hublarova et al. 2009). In the case of
HPV16, LCR has been observed to be methylated in some
primary cervical carcinomas, especially at E2-binding sites
(E2BS; Bhattacharjee and Sengupta 2006; Brandsma et al.
2009; Fernandez et al. 2009). It has been proved in vitro
that DNA methylation of the E2BS sequence inhibits the
binding of E2 protein (Thain et al. 1996) and that this
methylation is related to the reactivation of E6 and E7 in
advanced stages of carcinogenesis induced by HPV16. It
has been demonstrated that the use of DNA demethylating
agents can induce recruitment of E2 protein to its upstream
regulatory region-binding sites and reduce E6 and E7
expression (Fernandez et al. 2009). In the case of HPV18,
LCR has been found to be methylated in several primary
cell carcinomas and also in immortal descendant cells from
primary human foreskin keratinocytes transfected with the
entire HPV18 genome. However, the methylation of LCR
has not been found in C41 and HeLa cell lines and the level
of E6 and E7 was not modified by the treatment with DNA
demethylating agents (Fernandez et al. 2009).
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found in carcinomas, premalignant lesions, and asymp-
tomatic carriers in the case of HPV16 and HPV18
infection. HPV16 L1 sequence is methylated at interme-
diate level in asymptomatic infection, hypomethylated in
precursor lesions, and hypermethylated in carcinomas
(Badal et al. 2003; Kalantari et al. 2004). L1 gene of
HPV-18 is also hypermethylated in the carcinomas con-
trasting with its hypomethylated state in asymptomatic
infections and unmethylated in precursor lesions. These
results suggest that L1 DNA methylation may be a
powerful biomarker of the clinical progression of HPV-
18-associated disease and possibly HPV-16-associated
lesions as well (Turan et al. 2007).
Changes in DNA methylation pattern might also be
found in the host genome. Several tumor suppressor genes
possessing CpG islands in the promoter region are
frequently inactivated by hypermethylation in cervical
cancer cells (Szalmás and Kónya 2009; Woodman et al.
2007). Epigenetic silencing of genes involved in cell-cycle
regulation (e.g., p16; Nakashima et al. 1999a, b; Nuovo et
al. 1999), apoptosis (e.g., DcR1/DCR2, hTERT, p73;
Shivapurkar et al. 2004; Widschwendter et al. 2004; Liu
et al. 2004), DNA repair (MGMT; Narayan et al. 2003;
V i r m a n ie ta l .2001), development and differentiation
(RARβ; Narayan et al. 2003; Ivanova et al. 2002),
hormonal response (ERα; Zambrano et al. 2005)a n d
cellular signaling (RASSF1A; Cohen et al. 2003; Yu et al.
2003), invasion, and metastasis (DAPK; Narayan et al.
2003; Virmani et al. 2001) has been detected in cervical
cancer cells. However, it is still not clear if methylation of
tumor suppressor genes in cervical cancer cells is induced
by HPV viruses or it is an effect of carcinogenesis.
Difficulties with distinction may result from the fact that
almost all of cervical cancer cells are HPV positive at
diagnosis. Therefore, any comparison here will be non-
informative opposite to (EBV)-positive and negative gastric
cancers; hepatitis C positive and negative hepatocellular
carcinomas, and simian virus 40 (SV 40) positive and
negative mesotheliomas (Woodman et al. 2007).
Although, there is no evidence for HPV-induced meth-
ylation of tumor suppressor genes, it has been proved that
HPV viral proteins interact with cellular proteins which are
components of epigenetic machinery. For example, HPV16
E7 binds DNA methyltransferase 1 (DNMT1) and stim-
ulates its enzymatic activity (Burgers et al. 2006) and may
activate transcription of DNMT1 as well (Robertson 2001;
McCabe et al. 2005; Woodman et al. 2007). Moreover, E6
and E7 proteins interplay with histone modification
machinery (Table 2). E6 binds to and inhibits HAT proteins
Virus Viral protein Epigenetic interaction
HPV E7 Binds DNMT1 and stimulates DNA methyltransferase activity
Binds HDACs and Mi2 subunit of Nurd ATP-dependent
remodeling complex
Induces KMD6A and KDM6B histone demethylase expression
Induces expression of histone methyltransferase EZH2
E6 Interacts with p300/CBP and inhibits HAT activity
EBV LMP1 Activates DNMTs 1, 3a, and 3b
EBNA2 Interacts with p300 and activates transcription
EBNA3c Binds HDACs
KSHV LANA Activates DNMT3a
Interacts with SUV39H1, MeCP2, and mSin3
vIRFs Binds p300/CBP and inhibits HAT activity
HBV HBx Activates DNMT1
Regulates the expression of DNMT3a and DNMT3b
Interacts with p300/CBP
Interacts with HDAC
Adenovirus E1A Binds DNMT1 and stimulates DNA methyltransferase activity
Binds p300/CBP, TRRAP/GCN5, and PCAF HAT complexes
Binds to p400 and promotes the formation of a Myc–p400 complex
at Myc-target gene promoters
E4ORF3 Stimulates de novo H3K9me3 heterochromatin formation specifically
at p53 target promoters
HTLV-1 Tax Interacts with p300/CBP to repress transcription
Binds BRG1 subunit of chromatin-remodeling complexes
Table 2 Example of
interactions between oncogenic
viral proteins and host
epigenetic machinery
vIRF viral homologue of
interferon regulatory factor
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Furthermore, E7 oncoprotein has been demonstrated to
interact with pCAF acetyltransferase and to reduce its
acetyltransferase activity in vitro (Avvakumov et al. 2003).
E7 can also associate with HDACs. The association
between E7 and HDACs results in an increased level of
E2F2-mediated transcription in differentiating cells, which
is proposed to influence S-phase progression (Longworth et
al. 2005). It has been demonstrated that displacing of
HDAC from RB by HPV16 E7 protein leads to an increase
in H3 acetylation specifically at the E2F-targeted promoters
in human foreskin keratinocytes (Zhang et al. 2004). Most
recent study demonstrated that human papillomavirus E7
oncoprotein induces KMD6A and KDM6B histone deme-
thylase expression, thus leading to a decrease in
H3K27me3 level in HPV16-positive cervical lesions
(McLaughlin-Drubin et al. 2011). It has been shown that
KMD6B upregulation mediated by E7 oncoprotein corre-
lates with increased expression of the cervical carcinoma
biomarker p16INK4A. Also, several HOX genes regulated
by KDM6A or KDM6B have been shown to be expressed
at higher levels in such cells. Therefore, the authors suggest
that HPV16 E7 expression causes epigenetic reprogram-
ming of host cells at the level of histone methylation.
H P V 1 6E 7p r o t e i nh a sa l s ob e e ns h o w nt oi n d u c e
expression of histone methyltransferase EZH2 expression
in cervical cancer cells; however, the changes in the histone
modification pattern have not been examined (Holland et al.
2008). EZH2 overexpression does not result in increased
PRC2 activity but enhances PRC4 formation, which has
been demonstrated to cause histone H1K26 deacetylation
and methylation (Kuzmichev et al. 2005). Therefore,
increased EZH2 expression in E7-expressing cells may be
predicted to result in enhanced H1K26 methylation.
Epstein–Barr virus
The EBV is a human gamma-herpesvirus that predominantly
establishes latent infection in B lymphocytes and epithelial
cells. EBV is one of the most common viruses in humans.
Ninety percent of the world’s population is infected by it
(Young and Rickinson 2004; Williams and Crawford 2006;
Klein et al. 2007). EBV is associated with mononucleosis
and with several human cancers such as Burkitt’sl y m p h o m a
(BL; Bornkamm 2009), nasopharyngeal carcinoma (NPC),
T- and NK-cell lymphoma, and gastric carcinoma (Fukayama
et al. 2008). Moreover, EBV infection is involved in the
etiology of several lymphoid and epithelial malignancies in
immune-compromised humans, such as AIDS and posttrans-
plant patients (Niller et al. 2008).
Double-stranded DNA genome of EBV viruses is huge,
approximately 172 kb in size. In EBV infection, two stages
can be distinguished, i.e., lytic and latent. During lytic life
cycle, viruses are produced and finally released from the
infected cells and viral genome remains as an episome in
the host cell (Young and Rickinson 2004; Gatza et al. 2005;
Williams and Crawford 2006; Klein et al. 2007). During
latent infection, viral particles are not produced and several
viral proteins called “latent proteins,” which have onco-
genic activity, are expressed. The latency state is regulated
by six EBV nuclear antigens EBNAs: 1, 2, 3A, 3B, 3C, and
LP; three latent membrane proteins LMPs: 1, 2A, and 2B;
BARF-1 protein; two small RNA molecules: EBER 1 and
EBER2; and BART RNA transcripts. Additionally, EBV
codes for at least 20 miRNAs that are expressed in latently
infected cells (Tao et al. 1998; Klein et al. 2007; Bornkamm
2009). EBV genome also encodes for: immediate genes
(probably responsible for the switch between latent and
lytic cycle), the early genes (e.g., enzymes influencing the
host cell nucleotide metabolism and DNA synthesis), and
the late gene products (e.g., the virion structural proteins;
Young and Rickinson 2004; Gatza et al. 2005; Williams
and Crawford 2006; Klein et al. 2007).
The important role in carcinogenesis of all EBV positive
tumors but Burkitt’s lymphoma, which is driven by the
cMYC translocation, is played by LMP1 protein. LMP1 is
one of the major EBV oncoprotein, which controls cell
growth and promotes metastasis, apoptotic resistance, and
immune modulation (Arvanitakis et al. 1995; Martin and
Gutkind 2008). During B lymphocytes transformation
LMP1 activates cell signaling pathways such as NFκB,
inducing the expression of various genes that encode anti-
apoptotic proteins and cytokines (Young and Rickinson
2004). LMP1 acts as a constitutively active receptor that
mimics activated CD40, a member of the tumor necrosis
factor family (Mosialos et al. 1995; Martin and Gutkind
2008). Critical role in EBV-induced transformation plays
interaction between cytoplasmic carboxyl terminus of
LMP1 and tumor necrosis factor receptor-associated factor
and the tumor necrosis factor receptor-associated death
domain protein (Brown et al. 2001). These interactions
induce the activation of several key signaling molecules
such as PI3K, JNK, and JAKs leading to the activation of
transcription factors including NFκB, AP-1, and STATs
(Kilger et al. 1998), which have been extensively related to
human malignancies (Martin and Gutkind 2008).
In EBV-induced transformation as well as in EBV viral
life cycle, epigenetic mechanisms such as DNA methyla-
tion and histone modifications, which control expression of
latent viral oncogenes and miRNAs, play also an important
role (Park et al. 2007b; Niller et al. 2008). Methylation of
the EBV genome helps virus to hide from the host immune
system, inhibiting expression of viral latency proteins that
are recognized by cytotoxic T-cells (Robertson and
Ambinder 1997; Paulson and Speck 1999; Tao and
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Methylation pattern of EBV genome depends on the stages
of EBV latency (0, I, II, III) and the type of tumor (zur
Hausen 2006). It has been demonstrated that certain viral
promoters of latent circular EBV genomes may undergo
increased methylation (Niller et al. 2008). DNA methyla-
tion level in EBV genome increases dramatically from
asymptomatic infection to final neoplastic stages and has
been shown to be involved in regulation of viral genes
expression. One of the EBV genes whose expression is
epigenetically regulated is EBNA1. EBNA1 protein plays
crucial function in viral replication and episome mainte-
nance in latency. Expression of EBNA 1 is controlled by
four promoters; Cp, Wp, Qp, and Fp (Tao et al. 1998).
DNA methylation of these promoters regulates the expres-
sion of EBNA1 and eventually defines the type of latency
stage. CpG methylation downregulates gene expression and
induces the alternative transcription of EBNA1 from
various promoters during the different latency stages which,
at the same time, are associated with the pathology that the
virus induces from a simple infection to a lymphoma and
carcinoma (Li and Minarovits 2003; Yoshioka et al. 2003;
Niller et al. 2008). Wp, Cp, and X promoters have been
found to be methylated in I and II latency type in BL,
Hodgkin disease (HD), and NPC cells. Interestingly, Qp
promoter remains unmethylated independently of its activity.
It is suggested that it might be regulated by a putative
repressor protein and specifichistone modifications(Taoetal.
1998; Li and Minarovits 2003; Fejer et al. 2008; Fernandez
et al. 2009).
Epigenetic mechanisms are also used by EBV virus to
initiate lytic cycle and replication. This reactivation is
initiated by the expression of the immediate-early BZLF1
gene, which encodes for the transcription activator Zta.
This protein has the ability to bind to methylated sites and
activate the expression of the remaining lytic genes, thereby
inducing a lytic infection (Bhende et al. 2005; Countryman
et al. 2008; Dickerson et al. 2009; Heather et al. 2009).
DNA methylation also modulates expression of LMP2A in
BL, HD, and NPC, but has no affect on the expression of
major EBVoncogenic protein LMP1 (Young and Rickinson
2004). Analysis of CpG methylation pattern in EBV
genome showed that only five promoters do not possess
the DNA methylation mark: EBER1, EBER2, Qp, BZLF1,
and LMP2B/LMP1 (Fernandez et al. 2009).
Expression of many tumor suppressor genes involved in
the cell-cycle control, apoptosis, intracellular signaling,
proliferation, and surface adhesion might be downregulated
by DNA hypermethylation induced by EBV viral proteins.
It has been demonstrated that LMP1 oncoprotein induces
the activation of DNMT1 leading to an increase in
methylation of tumor suppressor genes promoters in
nasopharyngeal carcinoma cells (Tsai et al. 2002; Niemhom
et al. 2008). Moreover, reduction of E-cadherin expression
is the result of LMP1-induced hypermethylation by
activation of DNA methyltransferases DNMT1 3A and
3B. (Tsai et al. 2002). Besides E-cadherin promoter, other
tumor suppressor gene promoters such as RASSF1, retinoic
acid receptor, β2, p16
INK4, and p14 are also hyper-
methylated in NPC cells (Lo et al. 2001; Lo et al. 2002;
Kwong et al. 2002; Tong et al. 2002; Pai et al. 2007).
Similarly, LMP2A protein intermediates in the activation of
DNMT1 that leads to downregulation of PTEN gene
expression in gastric carcinoma cells (Hino et al. 2009).
Expression of host genes might also be affected by viral Zta
protein which downregulates early growth response 1
which is a cellular transcription factor involved in diverse
biological functions such as cell proliferation, apoptosis,
and differentiation (Chang et al. 2006).
EBV oncoproteins might also interact with compo-
nents of histone modification machinery. EBV viruses
possess the ability to change histone modifications and
chromatin structure. EBNA 2 and 3c alter histone
acetylation by interaction with p300/CBP complex or
with HDAC, respectively (Wang et al. 2000;K n i g h te ta l .
2003). Interestingly, all oncoproteins which interact with
epigenetic regulators are latent genes which are not
typically expressed in BL, gastric cancer, and most
nasopharyngeal carcinomas (Flanagan 2007). Latest
reports have demonstrated that LMP1, similar to HPV16
E7 oncoprotein, upregulate the expression of KDM6B
demethylase (specific for H3K27me3) in Hodgkin’s
lymphoma. It has been suggested that aberrant expression
of KDM6B stimulated by LMP1 may contribute to the
pathogenesis of HL. Moreover, the authors suggest that
the changes in the distribution of the H3K27me3 mark,
along with the dynamics of DNA methylation on early
viral promoters, might also play a role in the latent/lytic
switch (Anderton et al. 2011).
It has also been demonstrated that histone modifications
play significant role in the activity of EBV promoters and
expression of viral proteins (Gerle et al. 2007; Countryman
et al. 2008; Fejer et al. 2008). Histone H3 lysine 4
dimethylation (H3K4me2) has been associated with Qp
promoter activity and modulation of LMP2A expression.
Acetylation of histone 3 and 4 has been linked with Qp, Cp
promoter activity, and BZLF1 and LMP2A expression
(Fernandez and Esteller 2010; Gerle et al. 2007;C o u n t r y m a n
et al. 2008; Fejer et al. 2008).
EBVis the first virus that was reported to express miRNAs
(Pfeffer et al. 2004). More than 20 miRNAs are encoded by
EBV genome. They are differentially expressed in different
phases of the viral life cycle and between the types of latency
(Cai et al. 2006). EBV encoded miRNAs regulate both host
and viral genes and have also been suggested to be
implicated in the oncogenic properties of the virus (Pfeffer
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2008; Takacs et al. 2010;M o e n s2009).
Kaposi’s sarcoma-associated herpesvirus
KSHV also known as human herpesvirus 8 likewise EBV
belongs to the Herpesviridae family. KSHV is associated
with Kaposi sarcoma, one of the most common cancer in
human immune deficiency virus-infected patients, primary
effusion lymphoma (PEL), and some type of multicentric
Castleman’s disease (zur Hausen 2006). Similar to EBV
virus, KSHV is a dsDNA virus, whose infection persists for
life and it posseses two phase in its life cycle, i.e., latent
and lytic. Seven KSHV genes are closely associated with
latency and have potentially oncogenic activity: LANA,
vcyclinD, vFLIP (K13), Kaposin (K12), vIRF2 (K11.5),
vIRF3 (K10.5), and LAMP (K15) (Areste’ and Blackbourn
2009; Dourmishev et al. 2003; zur Hausen 2006) All of
these proteins have the ability to maintain lytic phase and to
control latent cycle replication. Replication and transcrip-
tion activator (RTA) is encoded by ORF50 of the viral
genome and is the lytic switch of KSHV (Sun et al. 1998).
Methylation of RTA (ORF50) promoter is used by virus to
maintain the latent cycle. The main latency protein LANA
(latency-associated nuclear protein) which remains unme-
thylated during KSHV infection also supports maintenance
of the latent cycle by the association with ORF50 promoter
or binding cellular factors which normally interact with
ORF50 (Lu et al. 2006; Pantry and Medveczky 2009).
It has been shown that KSHV may influence host DNA
methylation. LANA protein has been demonstrated to
associate with DNA methyltransferase DNMT3a, which
results in repression of approximately 80 cellular genes,
some of which are known targets of epigenetic inactivation
in various cancers (Shamay et al. 2006). Association and
relocalization of DNMT3a induced by LANA has an
influence on methylation of the H-cadherin gene promoter.
It has also been reported that LANA associates with the
TGF-β type II receptor (TβRII) promoter and induces its
methylation (Di Bartolo et al. 2008). Reduction of TβRII
expression in PEL cells results in defective TGF-β
signaling-pathway, which is important for preventing the
development of tumors because it inhibits growth and
promotes apoptosis (Di Bartolo et al. 2008). Another tumor
suppressor, p16INK4a, is also found to be inactivated by
promoter hypermethylation. However, it has not been
proved that LANA participates in its downregulation.
KSHV oncoproteins also interact with other compo-
nents of epigenetic machinery. LANA protein interacts
with the DNA methyl-binding protein MeCP2, the mSin3
transcriptional repression complex, and the histone
methyltransferase SUV39H1, thus enabling numerous
roles in epigenetic gene regulation (Flanagan 2007;L i
et al. 2000) .L A N A ,R T A ,K - b Z i p ,a n dv i r a lh o m o l o g u eo f
interferon regulatory factor encoded by ORFK9 interact
with histone acetyltransferase complex p300/CBP and
lead to reduction of its activity (Li et al. 2000; Hwang et
al. 2001;L i me ta l .2001; Gwack et al. 2001, 2002;P a n t r y
and Medveczky 2009). Moreover, miRNAs encoded by
KSHV virus are also involved in epigenetic regulation and
expression of oncogenes (Cai et al. 2006; Flanagan 2007;
Samols et al. 2007).
Hepatitis B virus
HBV is a member of Hepadnaviridae family. Viruses that
belong to this family cause acute and chronic infections of
the liver resulting in cirrhosis, hepatitis B, and HCC (Beck
and Nassal 2007; Seeger and Mason 2000; zur Hausen
2006). HBV and HCV are the main factors responsible for
HCC development in humans worldwide (Cougot et al.
2005; Gurtsevitch 2008). HBV contains a double-stranded
circular DNA genome of 3.2 kb and it replicates by reverse
transcription from an RNA intermediate (pregenomic
RNA), which is transcribed from covalently closed circular
HBV DNA (Yokosuka and Arai 2006).
In contrast to HCV infection during HBV replication,
epigenetic mechanisms such as DNA methylation or
histone modifications play an important role. Almost
completely unmethylated HBV genome occurs in the early
stages of carcinogenesis (e.g., hepatitis and cirrhosis);
whereas, HBV genome is more methylated in the estab-
lished liver tumors, both in clinical samples as well as in
cultured cancer cell lines (Fernandez et al. 2009). The
presence of DNA methylation at the C and S genes is
related to their lack of expression. Conversely, X gene that
encodes for HBx protein remains unmethylated (Fernandez
et al. 2009). HBx oncoprotein, which plays an important
role in carcinogenesis, is also a key factor responsible for
epigenetic alteration in viral and host genome (Jung et al.
2007; Park et al. 2007a; Zheng et al. 2009). HBx protein
interacts with DNMT1 and has influence on its expression.
Increased expression of DNMT1 induced by HBx inhibits
the expression of tumor suppressor genes such as p16 and
E-cadherin (Jung et al. 2007). Moreover, HBx directly
interacts and regulates the expression of DNMT3a and
DNMT3b which also modulates host genes expression (Park
et al. 2007a; Zheng et al. 2009) .T h es a m em e c h a n i s m sa r e
used by HBx to control viral genome methylation pattern
(Jung et al. 2007;P a r ke ta l .2007a; Zheng et al. 2009). HBx
has also been demonstrated to associate with components of
histone modification machinery, such as CBP/p300 HAT and
HDAC, thus influencing gene expression (Cougot et al. 2007;
Shon et al. 2009; Zheng et al. 2009).
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Human Adenoviruses are small DNA viruses with non-
enveloped icohasedral capsid (Russell 2009). More than 50
human serotypes of adenoviruses have been identified and
subdivided into groups A to F (Blackford and Grand 2009;
Russell 2009). Adenoviruses mostly cause respiratory
infections but a subset of them containing all subgroup A
and B (e.g., Ad12) are capable of promoting undifferenti-
ated tumors when injected into rodents (Graham et al. 1984;
Täuber and Dobner 2001; for a comprehensive review, see
Doerfler 2009). Nevertheless, role of adenoviruses in
human carcinogenesis is still unclear. It has been suggested
that adenoviruses might not cause human cancers due to the
fact that adenoviral DNA was generally not detected in
human tumor cells. However, latest data indicate that
adenoviruses can establish a form of latency in some
human cells (Garnett et al. 2009). Moreover, because
adenoviral DNA has been detected in brain tumors (Kosulin
et al. 2007) then potential involvement of adenoviruses in
human carcinogenesis should be considered. It has been
proposed that adenoviruses might perform “hit and run”
transformation of human cells (Nevels et al. 2001).
According to this hypothesis, cellular transformation may
be caused by transient viral infection, and after establishing
neoplastic state of the cell, viral DNA is not necessary for
the maintenance of transformed cellular phenotype. Studies
on Syrian hamster cells transformed by Ad12 have
demonstrated that despite of the gradual loss of multiple
copies of integrated Ad12 genomes from these cells, their
oncogenic potential was still maintained (Doerfler 2009).
The “hit and run” oncogenesis concept could explain the
role of adenoviruses as etiological agents in tumors that
lack any viral genes and proteins (Nevels et al. 2001).
Oncogenic properties of adenoviruses have been attrib-
uted mainly to the function of early region 1 (E1) which
encodes Ad E1A and E1B oncoproteins (Täuber and
Dobner 2001). Apart from E1A and E1B oncoproteins,
proteins encoded by E4 region have also been proposed to
be involved in cellular transformation. Early proteins E4-
ORF3 and E4-ORF6 of adenovirus Ad5 have been shown
to be able of replacing E1B function in transforming cells
and to increase cellular transformation mediated by E1A
and E1B as well (Täuber and Dobner 2001). Early viral
proteins E1A and E1B act as transcriptional factors
involved in the regulation of viral and cellular gene
expression and have been demonstrated to interact with
many cellular proteins including tumor suppressors, RB
proteins, and p53, respectively (Endter and Dobner 2004;
Martin and Berk 1998; Kosulin et al. 2007; Zheng 2010).
Epigenetic alterations such as changes in DNA methyl-
ation pattern of viral and host genome as well as histone
modification have been extensively demonstrated to occur
in adenovirus-transformed cells. It has been observed that
integrated adenoviral (Ad12) genome in hamster tumor
cells becomes de novo methylated, contrary to free viral
DNA, which is never methylated de novo (Doerfler 1991a,
b; 1996; 2009). Moreover, changes in methylation pattern
of cellular genome were found in cells which have Ad12
DNA integrated into host genome. However, it is unknown
whether changes in methylation profile of cellular genomes
are induced by insertion of adenoviral DNA or just by
insertion of any foreign DNA (Doerfler 2009).
Many studies have also demonstrated that adenoviral
oncoproteins interact with components of cellular epigenet-
ic machinery. These interactions are another example of
functional convergence of oncoproteins encoded by adeno-
viruses and HPV viruses. For instance, E1A correspond-
ingly to E7HPV16 protein associates with the DNMT1 and
increases its activity (Burgers et al. 2007). Moreover, E1A
similar to E6 HPV16 protein binds to and inhibits HAT
proteins CBP and p300. It has been shown that interaction
between E1A and CBP/p300 leads to reduction of histone
H3 lysine 18 acetylation (H3K18ac; Horwitz et al. 2008;
Ferrari et al. 2009). In addition, E1A also binds to several
other cellular proteins such as GCN5, PCAF, and p400,
which are involved in the regulation of chromatin structure
(Lang and Hearing 2003; Fuchs et al. 2001; Horwitz et al.
2008; Ferrari et al. 2009). Recent studies have demon-
strated that E1A function results in epigenetic reprog-
ramming of the host cell. It has been shown that E1A
binds in a time-dependent manner to promoter regions of
diverse sets of biologically related cellular genes which
causes genome-wide redistribution of RB proteins and
CBP/p300 on promoters, hypoacetylation of H3K18 in
these regions, and subsequent target genes repression,
which results in transcriptional reprogramming of the cell
(Ferrari et al. 2008). Furthermore, recent studies have
demonstrated that function of adenoviral E4-ORF3 protein
may also induce extensive epigenetic alteration in trans-
formed cells. It has been shown that E4-ORF3 stimulates
de novo H3K9me3 heterochromatin formation specifically
a tp 5 3t a r g e tp r o m o t e r s ,t h u sl e a d i n gt oa ni n h i b i t i o no f
p53 DNA binding and silencing of p53-target genes
transcription (Soria et al. 2010).
HTLV-1
HTLV-1 is a complex retrovirus with a single-stranded
RNA genome that is associated with multiple diseases
including an aggressive clonal malignancy of mature CD4+
T-lymphocytes called adult T-cell leukemia/lymphoma
(ATL). It is also responsible for causing chronic inflamma-
tory disease called HAM/TSP for HTLV-1-associated
myelopathy/tropical spastic paraparesis (Araujo and Silva
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retrovirus directly linked to oncogenesis. It is estimated that
about 20 million people worldwide are infected with
HTLV-1 (Proietti et al. 2005). In spite of this, ATL develops
only in minority of HTLV-1-infected individuals. The risk
of ATL in HTLV-1-infected people is estimated to be
approximately 6.6% for males and 2.1% for females
(Arisawa et al. 2000). The causative role of HTLV-1 in
ATL etiology is well documented. ATL develops only in
HTLV-1 carriers. Moreover, it has been shown that all ATL
cells contain integrated HTLV-1 provirus.
In contrast to mechanisms typical for animal retrovi-
ruses, HTLV-1-mediated oncogenesis involves virally
encoded proteins rather than insertional mutagenesis or
capturing and activating cellular proto-oncogenes (Yoshida
2001, 2005; Matsuoka and Jeang 2007). The main trans-
forming protein of HTLV-1 is Tax oncoprotein, but recent
studies evidence that the basic leucine zipper factor (HBZ)
also plays a role in this process (Matsuoka and Jeang 2007).
It has been proposed that Tax protein is needed to initiate
ATL transformation, and HBZ protein is involved in
leukemia maintenance (Matsuoka and Jeang 2007).
Although Tax protein is required for the virus to transform
T-cells, its transcripts are detected in only about 40% of all
ATLs. It has been demonstrated that Tax expression is
silenced in ATL cells, which enables transformed cells to
evade immunosurveillance (Koiwa et al. 2002; Takeda et al.
2004; Taniguchi et al. 2005; Matsuoka and Jeang 2007).
Tax protein contributes to the initiation of T-cell
transformation through various mechanisms, by deregulat-
ing the function and expression of key cellular factors
involved in cell growth and proliferation, apoptosis, DNA
repair, and cell division (Matsuoka and Jeang 2007). It has
been demonstrated that Tax protein associates with cen-
trosomes, causing their amplification and as a consequence
multipolar mitosis and aneuploidy. It abrogates DNA repair
which contributes to clastogenic DNA damage in HTLV-1-
infected cells. It is also responsible for inactivation of
factors involved in DNA damage response, e.g., p53, thus
contributing to suppression of apoptosis and senescence.
Other reported mechanisms of Tax-mediated transformation
include activation of cyclin-dependant kinases, NFκB, and
Akt signaling which promote cell survival and proliferation
of HTLV-1 infected cells.
Many studies report that Tax protein also influences host
cell epigenetic machinery. It has been shown that Tax
protein forms complex with the phosphorylated form of the
cellular transcription factor pCREB that recruits the cellular
histone acetyltransferases CBP/p300 to promote changes in
chromatin architecture characteristic for transcriptional
activation. This mechanism of Tax-mediated change in
histone acetylation is used by HTLV-1 to activate transcrip-
tion of viral genes from viral long terminal repeats LTR and
is required for high-level transcription of the proviral DNA.
Recent evidences also show that Tax interacts with BRG1
subunit of chromatin-remodeling complexes. This interac-
tion leads to HTLV-1 nucleosome remodeling and is
required for Tax transactivation.
It has also been demonstrated that Tax protein can recruit
histone methyltransferase SUV39H1 to 5′LTR and induce
H3K9 methylation whereby it modulates its own expression
which plays a role in the regulation of viral latency (Kamoi
et al. 2006).
Summary
The studies in characterizing the molecular mechanisms of
viral-induced carcinogenesis provide increasing evidence
for the importance of the interactions between viruses and
host cells at the epigenetic level. It is now apparent that
viral oncoproteins target the elements of cellular epigenetic
machinery changing their expression and/or activity thus
leading to alterations in the epigenetic state of the host cell.
Viral-encoded oncoproteins exploit specific epigenetic
processes to force normal quiescent cells to replicate as
well as to regulate viral genes expression during infections.
DNA methylation in viral promoters modulates viral genes
expression and is the mechanism used by many oncoviruses
to avoid detection by the host immune system.
Epigenetic alterations in DNA methylation and histone
modifications, leading to aberrant profiles of gene expres-
sion, are highly conserved function in tumor-associated
viruses belonging to distinct evolutionary groups. Common
targets for the viral oncoproteins are DNA methyltrans-
ferases (maintenance DNA methyltransferase, DNMT1,
and/or de novo DNA methyltransferases, DNMT3a,
DNMT3b) and histone-modifying enzymes, such as
HDAC, HAT, histone methyltransferases, and demethy-
lases. Emerging data also point toward a role of miRNA in
the regulation of viral life cycle and pathogenesis of several
virus-associated cancers. However, while changes in DNA
methylation pattern and some histone modification changes
induced by viral infection are better recognized, the
function of miRNA still remains poorly understood.
The fact that oncovirus-induced epigenetic alterations
within host cell during carcinogenesis are also a character-
istic for most non-viral cancers demonstrates the similarity
between the viral and tumor cell programs at the epigenetic
level. Aberrant methylation patterns are an important and
frequent event both in virus-associated and non-viral
cancers (Robertson 2001; Jones and Baylin 2002). Many
studies demonstrate an essential role of elevated Dnmt1,
Dnmt3a, and Dnmt3b expression and activity in the
development of cancers (Robertson 2001; Esteller 2006).
The resulting hypermethylation of CpG island promoter
Clin Epigenet (2011) 2:233–247 241observed in many cancers has been widely demonstrated to
cause silencing of tumor suppressor genes. Aberrant histone
modifications in particular histone acetylation, which lead
to misregulation in gene expression, are also a characteristic
feature of human cancer cells. Inhibition of p300/CBP
histone acetyltransferase activity is observed in many non-
viral cancers. The germline mutations of CBP are found in
Rubinstein–Taybi syndrome, a developmental disorder
characterized by an increased predisposition to childhood
malignancies, e.g., solid tumors, leukemias, and lympho-
mas. Moreover, frequent somatic mutations of p300/CBP
have been detected in breast, colorectal, and gastric
carcinomas (Iyer et al. 2004). Altered expression and
mutations of genes that encode HDACs have also been
associated with carcinogenesis (Ropero and Esteller 2007
and references therein). Overexpression of individual
HDACs has been detected in many different tumors, but
there are also evidences that alterations that result in the
loss of function of class I HDACs may also be associated
with cancer development. It has been proposed that the loss
of class I HDAC function could induce the hyperacetylation
and activation of genes regulated by RB protein, thus
leading to cell-cycle deregulation (Ropero and Esteller
2007). Aberrant histone methylation has also been widely
demonstrated to contribute to carcinogenesis. Deregulation
o fH 3 K 2 7m e t h y l a t i o nc a u s e db yb o t hi n c r e a s e da n d
decreased activity of enzymes controlling H3K27 methyl-
ation is observed in many cancers, which demonstrates that
precise balance of this methylation plays an important role
in normal cell growth (Simon and Lange 2008; Martinez-
Garcia and Licht 2010).
In light of the discussed significance of epigenetic
mechanisms in tumorigenesis, oncogenic viruses can be
seen as important players changing the function of cellular
epigenetic machinery, thereby contributing to cancer devel-
opment. The models of virus-induced epigenetic reprog-
ramming may also apply to non-viral mechanisms of
oncogenesis. Therefore, the results of studies aimed at
complete understanding of the viral interference with the
cellular epigenetic processes will have a powerful impact
also on understanding of the epigenetic mechanisms
involved in human non-viral carcinogenesis.
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